Why the Terminology Gets Confusing

Growth hormone itself is a peptide in the biochemical sense: it's a 191-amino-acid chain produced by somatotroph cells in the anterior pituitary. So calling it a "peptide" is technically accurate. The problem is that the fitness and biohacking communities have borrowed the word "HGH peptide" to mean something narrower: compounds that stimulate growth hormone secretion rather than replace it. These two categories behave differently in the body, carry different legal statuses, and have very different research records.

Recombinant human growth hormone (rhGH) has been manufactured since the mid-1980s and is sold under brand names including Norditropin, Genotropin, and Humatrope. It requires a prescription in the United States and is FDA-approved for a defined list of indications, including growth hormone deficiency in children and adults, Turner syndrome, and HIV-associated wasting. The secretagogue peptides discussed in most online forums are a separate class entirely, and the majority have never been approved for any clinical use.

What Are Growth Hormone Secretagogues?

Growth hormone secretagogues (GHS) are compounds that stimulate the pituitary to release growth hormone through one of two main pathways. The first pathway runs through the growth hormone-releasing hormone receptor (GHRHR). Peptides that activate this receptor mimic or amplify the action of endogenous GHRH, the hypothalamic signal that normally tells the pituitary it's time to pulse growth hormone into circulation. Sermorelin and tesamorelin are examples in this class. Sermorelin is a 29-amino-acid fragment of GHRH; tesamorelin is a stabilized full-length GHRH analog approved as the branded drug Egrifta for HIV-associated lipodystrophy.

The second pathway runs through the ghrelin receptor, formally called the growth hormone secretagogue receptor type 1a (GHS-R1a). Peptides that bind here are called GHRPs, or growth hormone-releasing peptides. GHRP-2, GHRP-6, ipamorelin, and hexarelin all fall into this group. They were originally synthesized in the 1970s and 1980s during research into how the pituitary could be stimulated pharmacologically. Ipamorelin is often cited as the most selective of the group because it produces less cortisol and prolactin release than older GHRPs, though this comparison comes primarily from animal studies rather than large human trials.

A third subgroup, the non-peptide secretagogues, includes compounds like MK-677 (ibutamoren). These are small molecules, not peptides at all, that also activate GHS-R1a. They're often grouped with GHRPs in online discussions, which adds another layer of confusion to the terminology.

How the Mechanisms Differ From Exogenous HGH

When someone injects recombinant HGH, they're adding a fully formed hormone to their bloodstream. The pituitary plays no role in that transaction. The exogenous HGH circulates, binds to growth hormone receptors in tissues, and triggers downstream effects including IGF-1 production in the liver. Because the pituitary detects elevated growth hormone levels, it responds by reducing its own output through negative feedback. Long-term use of exogenous rhGH can therefore suppress the pituitary's natural secretory activity.

Secretagogue peptides work upstream. They arrive at the pituitary (or hypothalamus, in the case of GHRH analogs) and encourage the gland to release its own stored growth hormone in pulses that more closely resemble the body's natural secretory pattern. The pituitary's negative feedback system remains active, which theoretically limits how far growth hormone can be pushed above physiological ranges. This is one reason researchers have studied secretagogues as potentially having a different side-effect profile than direct rhGH administration, though that hypothesis has not been confirmed in large, long-term human trials.

CJC-1295, a modified GHRH analog, illustrates another layer of complexity. It was engineered with a drug affinity complex that allows it to bind to albumin in the blood, extending its half-life from minutes to days. This changes the secretion pattern significantly: instead of a brief pulse, growth hormone release is prolonged. Whether that extended pattern is beneficial, neutral, or harmful compared to pulsatile release is an open research question. Most published data on CJC-1295 comes from small Phase I and Phase II studies.

Regulatory Status: What's Approved and What Isn't

Recombinant human growth hormone products are FDA-approved prescription drugs. Prescribing rhGH for indications outside the approved label, such as anti-aging or athletic performance, is legal for physicians but controversial, and obtaining it without a prescription is not legal in the United States. The FDA has also issued guidance classifying HGH as a controlled substance under the Anabolic Steroid Control Act framework for purposes of distribution, making unauthorized distribution a federal offense.

Among the secretagogue peptides, tesamorelin has the clearest regulatory standing: the branded drug Egrifta (tesamorelin) is FDA-approved specifically for reducing excess abdominal fat in HIV-positive adults with lipodystrophy. Sermorelin was previously approved as Geref for diagnosing growth hormone deficiency and for treating growth hormone deficiency in children, though that approval was withdrawn by the manufacturer for commercial reasons, not safety concerns. The FDA has since placed sermorelin on a list of compounds that cannot be compounded under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

GHRPs such as GHRP-2, GHRP-6, ipamorelin, and hexarelin have no FDA approval for any indication. They are sold as research chemicals, meaning they are legal to purchase for laboratory research but are not approved for human use. The FDA's 2023 and 2024 actions on compounded peptides placed several of these compounds on lists restricting their use in compounding pharmacies, a regulatory shift that significantly affected how they were previously accessed in clinical settings. Researchers and clinicians following this space should check current FDA guidance directly, as the regulatory picture has been evolving.

What Does the Human Evidence Actually Show?

The evidence base for secretagogue peptides is thinner than online discussions suggest. Tesamorelin has the strongest human data: multiple randomized controlled trials, including a 2010 study published in the New England Journal of Medicine involving 412 HIV-positive participants, demonstrated significant reductions in visceral adipose tissue compared to placebo. That's a specific population with a specific condition, and the results don't automatically generalize to healthy adults.

Sermorelin's human data is older and mostly focused on growth hormone deficiency diagnosis and pediatric growth failure, the indications it was originally approved for. Studies in healthy older adults showed it could raise IGF-1 levels, but the clinical significance of that change for outcomes like body composition or bone density in non-deficient populations is not well established by current evidence.

For GHRPs, most mechanistic work was done in animals or in small, short-duration human studies. A 1997 paper in the Journal of Clinical Endocrinology and Metabolism examined GHRP-2 in healthy volunteers and confirmed it raised growth hormone levels acutely, but acute hormone elevation in a small study is a long way from evidence of meaningful clinical benefit. Ipamorelin's human data is similarly limited: most published work is preclinical, and the compound has not completed large Phase III trials. Anyone evaluating these compounds should weight animal and small human studies accordingly, as preclinical results frequently do not replicate at scale in humans.

Frequently asked questions

Can a doctor legally prescribe GHRP-6 or ipamorelin in the United States?

No, not as approved drugs. Neither GHRP-6 nor ipamorelin has FDA approval for any indication, so they cannot be legally prescribed as finished pharmaceutical products. They were previously available through compounding pharmacies operating under certain exemptions, but FDA actions in 2023 and 2024 restricted the compounding of several peptides including ipamorelin. The current legal status of compounded versions is subject to ongoing regulatory change, so anyone with clinical questions should consult a licensed healthcare provider and check current FDA guidance.

Does using a secretagogue peptide raise IGF-1 the same way exogenous HGH does?

Both can raise IGF-1, but through different routes and to different degrees. Exogenous rhGH delivers a large, sustained hormone load that drives significant IGF-1 production in the liver. Secretagogue peptides stimulate the pituitary to release its own growth hormone in pulses, and the pituitary's negative feedback system limits how high levels can go. Studies on GHRH analogs like sermorelin in older adults have shown modest IGF-1 increases, generally smaller than those seen with direct rhGH administration at therapeutic doses. The clinical relevance of those differences for any specific outcome has not been established in large trials.

Is MK-677 (ibutamoren) the same type of compound as a GHRP?

MK-677 activates the same ghrelin receptor (GHS-R1a) that GHRPs target, so it produces a similar downstream effect of stimulating growth hormone release. The key structural difference is that MK-677 is a small non-peptide molecule, not a peptide chain. It's orally active, which peptides generally are not, because peptides are broken down in the digestive tract before reaching systemic circulation. MK-677 has no FDA approval and is classified as a research chemical. It is not the same compound as any approved drug.

Sources

  1. Falutz et al., 2010, New England Journal of Medicine (tesamorelin RCT in HIV lipodystrophy) Phase III RCT supporting tesamorelin's approved indication
  2. Bowers et al., 1997, Journal of Clinical Endocrinology and Metabolism (GHRP-2 in humans) Early human data on GHRP-2 acute GH release
  3. Corpas et al., 1992, Journal of Clinical Endocrinology and Metabolism (GHRH analog in older adults) Human data on GHRH-analog effects on IGF-1 in aging

Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds that are not approved for human use outside specific prescribed contexts. Always consult a qualified, licensed clinician before making any health decision.